BD9 – Adding IL-13 binding site to anti TSLP mAb with only 6 mutations
IL-13 & TSLP Multibody for inflammatory indications
Multibody developed in partnership with Eli Lilly
Biolojic Design and Eli Lilly announced a research collaboration and license agreement to discover and develop a potential novel antibody-based therapy for the treatment of diabetes